RESUMO
UNLABELLED: The aim of this study was to evaluate fracture risk in patients with Guillain-Barré syndrome (GBS). No association with risk of fracture was observed for GBS patients compared with controls. Only GBS patients using pain treatment had a doubled risk of fracture. INTRODUCTION: Symptoms of Guillain-Barré syndrome (GBS) may vary from mild difficulty in walking to complete paralysis, which may increase the risk of fractures. Therefore, the aim of this study was to evaluate fracture risk in patients with GBS. METHODS: We conducted a retrospective cohort study using the UK Clinical Practice Research Datalink (1987-2012). Each patient with GBS was matched by year of birth, sex, and practice, up to six patients without a history of GBS. Outcome measure was any fracture. RESULTS: There were no associations between GBS and any fracture, adjusted hazard ratio (AHR) 1.01 (95 % confidence interval [CI] 0.77-1.33), or osteoporotic fracture, AHR 0.76 (95 % CI 0.50-1.17), compared with controls. Stratification to gender, age, and duration since diagnosis did not show an association either. Only for GBS patients using pain treatment, risk of fracture was doubled AHR 1.97 (95 % confidence CI 1.21-3.21) compared with controls. The risk of fracture in GBS patients exposed to pain treatment was equivalent to risk of fracture among controls exposed to pain treatment. CONCLUSIONS: No association with risk of fracture was observed for GBS patients compared with controls. Only GBS patients using pain treatment had a doubled risk of fracture, but their risk was equivalent to fracture risk among controls exposed to pain treatment.
Assuntos
Fraturas Ósseas/epidemiologia , Síndrome de Guillain-Barré/epidemiologia , Adolescente , Adulto , Idoso , Analgésicos/efeitos adversos , Analgésicos/uso terapêutico , Estudos de Casos e Controles , Comorbidade , Feminino , Fraturas Ósseas/induzido quimicamente , Síndrome de Guillain-Barré/tratamento farmacológico , Humanos , Masculino , Pessoa de Meia-Idade , Fraturas por Osteoporose/induzido quimicamente , Fraturas por Osteoporose/epidemiologia , Medição de Risco/métodos , Fatores de Risco , Reino Unido/epidemiologia , Adulto JovemRESUMO
UNLABELLED: The aim of the study was to determine fracture risk in incident muscular dystrophy (MD) patients. Patients with MD are at a 1.4-fold increased risk of fracture as compared with population-based control patients. Risk further increased among elderly and female patients and among patients exposed to oral glucocorticoids. INTRODUCTION: Muscular dystrophies (MDs) are inherited diseases causing muscle weakness and thereby increase the risk of falling and detrimental effects on bone. Both are recognised risk factors for fracture. Therefore, the aim of this study was to determine the hazard ratio of fracture in patients with MD. METHODS: We conducted a retrospective cohort study using the UK General Practice Research Database (1987-2012). Each patient with MD was matched by year of birth, sex and practice to up to six patients without a history of MD. Outcome measure was all fractures. RESULTS: As compared with control patients, risk of any fracture was statistically significantly increased in MD patients (adjusted hazard ratio [AHR], 1.40; 95 % confidence interval [CI], 1.14-1.71). An increased risk of fracture was observed among MD patients with female gender (AHR, 1.78; 95 % CI, 1.33-2.40) and an increasing age as compared with control patients. Stratification to Duchenne MD showed no association with fracture, whereas risk of fracture was increased twofold among patients with myotonic dystrophy (AHR, 2.34; 95 % CI, 1.56-3.51). MD patients had an almost tripled risk of fracture when they used oral glucocorticoids in the previous 6 months as compared to non-users with MD. CONCLUSION: Patients with MD are at a 1.4-fold increased risk of fracture as compared with population-based control patients. Especially in older age groups and female gender, the fracture risk of MD versus non-MD patients is increased, whereas exposure to glucocorticoids further increased fracture risk among MD patients.
Assuntos
Fraturas Ósseas/etiologia , Distrofias Musculares/complicações , Adulto , Distribuição por Idade , Comorbidade , Bases de Dados Factuais , Uso de Medicamentos/estatística & dados numéricos , Feminino , Fraturas Ósseas/epidemiologia , Glucocorticoides/efeitos adversos , Humanos , Masculino , Pessoa de Meia-Idade , Distrofias Musculares/epidemiologia , Distrofia Muscular de Duchenne/complicações , Distrofia Muscular de Duchenne/epidemiologia , Distrofia Miotônica/complicações , Distrofia Miotônica/epidemiologia , Fraturas por Osteoporose/epidemiologia , Fraturas por Osteoporose/etiologia , Estudos Retrospectivos , Medição de Risco , Distribuição por Sexo , Reino Unido/epidemiologiaRESUMO
UNLABELLED: The aim of the study was to determine fracture risk in incident Parkinson's disease (PD) patients. This study showed that fracture risk assessment may be indicated among patients with PD, in particular when they have recently used selective serotonin re-uptake inhibitors or high-dose antipsychotics, or have a history of fracture, falling, low body mass index (BMI) or renal disease. INTRODUCTION: PD is a movement disorder associated with falling and detrimental effects on bone. Both are recognized risk factors for fracture. Therefore, the aim was to determine fracture risk in incident PD patients stratified by treatment, severity, duration of disease and related comorbidities. METHODS: We conducted a retrospective cohort study using the UK General Practice Research Database (1987-2011). Each PD patient was matched by age, sex, calendar time and practice to a control patient without history of PD. RESULTS: We identified 4,687 incident PD patients. Compared to controls, a statistically significant increased risk was observed for any fracture (adjusted hazard ratio [AHR], 1.89; 95 % confidence interval [CI], 1.67-2.14), osteoporotic fracture (AHR, 1.99; 95 % CI, 1.72-2.30) and hip fracture (AHR 3.08; 95 % CI, 2.43-3.89). Fracture risk further increased with history of fracture, falling, low BMI, renal disease, antidepressant use and use of high-dose antipsychotics. CONCLUSION: This study showed that incident PD patients have a statistically significant increased risk of fracture. Therefore, fracture risk assessment may be indicated among PD patients, who, besides the general risk factors for fracture, like increasing age and female gender, have recently used selective serotonin re-uptake inhibitors or high-dose antipsychotics or have a history of fracture, falling, low BMI or renal disease.
Assuntos
Fraturas Ósseas/etiologia , Doença de Parkinson/complicações , Acidentes por Quedas , Adulto , Fatores Etários , Idoso , Idoso de 80 Anos ou mais , Antidepressivos/efeitos adversos , Antipsicóticos/efeitos adversos , Estudos de Casos e Controles , Bases de Dados Factuais , Feminino , Fraturas Ósseas/epidemiologia , Humanos , Masculino , Pessoa de Meia-Idade , Inibidores da Monoaminoxidase/efeitos adversos , Fraturas por Osteoporose/epidemiologia , Fraturas por Osteoporose/etiologia , Doença de Parkinson/tratamento farmacológico , Doença de Parkinson/epidemiologia , Medição de Risco/métodos , Inibidores Seletivos de Recaptação de Serotonina/efeitos adversos , Fatores Sexuais , Reino Unido/epidemiologiaRESUMO
We reviewed eight studies on transcranial sonography (TCS) as a tool for differentiating idiopathic Parkinson's disease (IPD) from atypical parkinsonian syndromes (APS) and included some first data on TCS findings in the subforms of PSP. Changes of specific structures on TCS like the substantia nigra (SN), lenticular nucleus (LN), and the third ventricle are discussed as well as how they can contribute to differentiate between IPD, multiple system atrophy (MSA), progressive supranuclear palsy (PSP), Lewy body disease (LBD), and corticobasal degeneration (CBD). We finish with an algorithm that may be used to employ TCS as a diagnostic instrument delineating IPD from the APS and discerning among the APS themselves. As TCS is at present the most promising tool for this particular diagnostic problem, this algorithm might be a suitable hypothesis to study in future research.
Assuntos
Doença de Parkinson/diagnóstico por imagem , Doença de Parkinson/diagnóstico , Transtornos Parkinsonianos/diagnóstico por imagem , Transtornos Parkinsonianos/diagnóstico , Ultrassonografia Doppler Transcraniana/métodos , Encéfalo/patologia , Encéfalo/fisiopatologia , Diagnóstico Diferencial , Humanos , Valor Preditivo dos Testes , Ultrassonografia Doppler Transcraniana/normasRESUMO
BACKGROUND AND PURPOSE: Overlooking a potential diagnosis of cauda equina syndrome (CES) can result in severe long-term neurologic deficits. There is a growing trend to order urgent magnetic resonance imaging (MRI) scans of the lumbar spine in any patient presenting with signs suspicious for CES. A substantial number of these MRI scans do not show cauda compression. The purpose of this study is to assess whether clinical characteristics can predict MRI-confirmed cauda compression. METHODS: We retrospectively studied 58 consecutive cases of suspected CES who presented at our hospital's emergency room. RESULTS: Eight of 58 patients had cauda compression on MRI. When measured, MRI + CES patients (6) had more than 500 ml urinary retention. Moreover, when these patients had at least two of the following characteristics: bilateral sciatica, subjective urinary retention or rectal incontinence symptoms, MRI was more probable to demonstrate cauda compression with an OR of 48.00, 95% (CI 3.30-697.21), which was also significant (P of 0.04). The presence of other symptoms or signs alone was not significantly different between both groups. CONCLUSION: In our series, urinary retention of more than 500 ml alone or in combination with two or more specific clinical characteristics were the most important predictors of MRI confirmed cauda compressions.
Assuntos
Incontinência Fecal/etiologia , Síndromes de Compressão Nervosa/complicações , Polirradiculopatia/complicações , Ciática/etiologia , Retenção Urinária/etiologia , Humanos , Imageamento por Ressonância Magnética , Síndromes de Compressão Nervosa/diagnóstico , Polirradiculopatia/diagnóstico , Valor Preditivo dos Testes , Estudos RetrospectivosRESUMO
Since the early 1970s, the literature has suggested an association between Parkinson's Disease (PD) and/or levodopa-use and an increased risk for the development of malignant melanoma. In some countries, this possible association has even led to a warning in the drug insert leaflet of the possible risk. Recently, five studies have been published that have investigated both associations and three conclusions can be drawn. Firstly, there appears to be an increased risk in the development of melanomas in patients with PD. Secondly, this increased risk is already present before the PD is diagnosed. Finally, it is unlikely that levodopa plays any role in this phenomenon. It is not known which factors are responsible for this increase in the development of melanomas in PD patients and this needs further investigation. We recommend the removal of the warning from the drug insert leaflet, since this can lead to unnecessary fear on the part of the patients and physician resistance to prescribing this medication.
Assuntos
Levodopa/efeitos adversos , Melanoma/induzido quimicamente , Doença de Parkinson/complicações , Doença de Parkinson/tratamento farmacológico , Neoplasias Cutâneas/induzido quimicamente , Animais , Humanos , Melanoma/epidemiologia , Melanoma/etiologia , Doença de Parkinson/epidemiologia , Fatores de Risco , Neoplasias Cutâneas/epidemiologia , Neoplasias Cutâneas/etiologiaRESUMO
The ictal bradycardia syndrome is an uncommon diagnosis in which bradycardia is accompanied by simultaneous epileptic discharges in the EEG. We describe a patient who was referred to the emergency ward because of syncope. Ictal semeiology and EEG-EG findings are discussed and compared with those published in the literature. Therapeutic options are discussed in relation with those published in the literature. The ictal bradycardia syndrome is probably underdiagnosed, while its recognition is of utmost importance because of potential life threatening complications such as asystole. Up to now, its aetiology is poorly understood, its ictal semeiology is often described insufficiently and its therapy is still discussed.
Assuntos
Bradicardia/etiologia , Bradicardia/fisiopatologia , Córtex Cerebral/fisiopatologia , Epilepsia/complicações , Epilepsia/fisiopatologia , Potenciais Evocados/fisiologia , Doenças do Sistema Nervoso Autônomo/etiologia , Doenças do Sistema Nervoso Autônomo/fisiopatologia , Vias Autônomas/fisiopatologia , Eletroencefalografia , Epilepsia/diagnóstico , Humanos , Masculino , Pessoa de Meia-Idade , Síndrome , Lobo Temporal/fisiopatologiaRESUMO
BACKGROUND: Spinal cord stimulation (SCS) has been used since 1967 for the treatment of patients with chronic pain. However, long-term effects of this treatment have not been reported. The present study investigated the long-term effects of cervical and lumbar SCS in patients with complex regional pain syndrome type I. METHODS: Thirty-six patients with a definitive implant were included in this study. A pain diary was obtained from all patients before treatment and 6 months and 1 and 2 years after implantation. All patients were asked to complete a seven-point Global Perceived Effect (GPE) scale and the Euroqol-5D (EQ-5D) at each post-implant assessment point. RESULTS: The pain intensity was reduced at 6 months, 1 and 2 years after implantation (P<0.05). However, the repeated measures ANOVA showed a statistically significant, linear increase in the visual analogue scale score (P=0.03). According to the GPE, at least 42% of the cervical SCS patients and 47% of the lumbar SCS patients reported at least 'much improvement'. The health status of the patients, as measured on the EQ-5D, was improved after treatment (P<0.05). This improvement was noted both from the social and from the patients' perspective. Complications and adverse effects occurred in 64% of the patients and consisted mainly of technical defects. There were no differences between cervical and lumbar groups with regard to outcome measures. CONCLUSION: SCS reduced the pain intensity and improves health status in the majority of the CRPS I patients in this study. There was no difference in pain relief and complications between cervical and lumbar SCS.
Assuntos
Síndromes da Dor Regional Complexa/terapia , Terapia por Estimulação Elétrica/métodos , Medula Espinal , Adulto , Vértebras Cervicais , Terapia por Estimulação Elétrica/efeitos adversos , Eletrodos Implantados , Feminino , Seguimentos , Humanos , Vértebras Lombares , Masculino , Pessoa de Meia-Idade , Medição da Dor , Estudos Prospectivos , Resultado do TratamentoRESUMO
Adults suffering from Attention Deficit Hyperactivity Disorder (ADHD) are known to have disturbed central dopaminergic transmission. With Single Photon Emission Computed Tomography (SPECT) we studied brain dopamine transporter and receptor activity in six boys with ADHD. Three months after initiation of treatment with methylphenidate we found a down-regulation of the post-synaptic dopamine receptor with a maximum of 20 % and a down-regulation of the dopamine transporter with a maximum of 74.7 % in the striatal system. This corresponded to a positive clinical response evaluated by neuropsychological questionnaires and tests. We suggest that dopamine transporter imaging by SPECT might be used to monitor psychostimulant treatment in children suffering from ADHD.
Assuntos
Transtorno do Deficit de Atenção com Hiperatividade/tratamento farmacológico , Estimulantes do Sistema Nervoso Central/farmacologia , Estimulantes do Sistema Nervoso Central/uso terapêutico , Regulação para Baixo/efeitos dos fármacos , Glicoproteínas de Membrana , Proteínas de Membrana Transportadoras/efeitos dos fármacos , Metilfenidato/farmacologia , Metilfenidato/uso terapêutico , Proteínas do Tecido Nervoso , Receptores Dopaminérgicos/efeitos dos fármacos , Transtorno do Deficit de Atenção com Hiperatividade/diagnóstico por imagem , Transtorno do Deficit de Atenção com Hiperatividade/fisiopatologia , Criança , Proteínas da Membrana Plasmática de Transporte de Dopamina , Regulação para Baixo/fisiologia , Seguimentos , Humanos , Masculino , Proteínas de Membrana Transportadoras/fisiologia , Receptores Dopaminérgicos/fisiologia , Transdução de Sinais/efeitos dos fármacos , Transdução de Sinais/fisiologia , Transmissão Sináptica/efeitos dos fármacos , Transmissão Sináptica/fisiologia , Fatores de Tempo , Tomografia Computadorizada de Emissão de Fóton Único , Resultado do TratamentoRESUMO
In two patients, a 60-year-old woman and a 63-year-old man, cerebral blindness was diagnosed. The first patient developed the disorder shortly after cerebral angiography was carried out to diagnose a carotid-cavernous fistula. The symptoms disappeared after three days. The second patient suffered from a reversible posterior leuko-encephalopathy syndrome. He recovered his vision without specific treatment. Cortical or cerebral blindness is a form of blindness caused by a lesion in the cerebral part of the visual pathways. Although in itself rare, cerebral blindness occurs frequently as a complication of non-neurologic diseases or interventions. Physicians who are unaware of this syndrome tend to diagnose these patients as 'hysteric', since normal pupillary reactions and normal eye movements accompany the loss of vision. If the blindness is not caused by an ischaemic infarct, it is usually reversible.